CAMBRIDGE, Mass., Aug. 25, 2022 -- Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced...
Taking Aim at Melanoma - The Scientist - Magazine of the Life Sciences
News | 04. 01. 2011
Understanding oncogenesis at the molecular level offers the prospect of tailoring treatments much more precisely for patients with advanced cases of this deadliest of skin cancers.
